Traditional Chinese medicine has been passed down through thousands of years of treatment experience in China. The biggest advantage is that it has its own independent treatment system, which is cheap and effective. Especially in the treatment of COVID-19 patients, traditional Chinese medicine has played an important role. China attaches great importance to the protection of traditional Chinese medicinal materials, and there are corresponding protection measures for precious medicinal materials in various places. China has already supported the development of traditional Chinese medicine, and listed the intellectual property rights of traditional Chinese medicine as a special protection object.
See Also: Top 15 Famous Chinese Medicine Experts in China
On the basis of in-depth excavation of the treasure trove of traditional Chinese medicine formulas in China, using modern medical technology to deeply analyze the therapeutic pharmacology of traditional Chinese medicine, so as to develop traditional Chinese medicine preparations that conform to the medicinal habits of modern people, it will not only promote the gradually marginalized traditional Chinese medicine The industry has regained its vitality, and it has also enabled domestic pharmaceutical manufacturers who have been relying on generic drugs for a living to serve the golden rice bowl developed by themselves. With the support of national policies and heavy funds, facing the huge pharmaceutical market demand, I believe that traditional Chinese medicine will develop better.
This post will introduce you to the top ten Chinese medicine companies in China.

1. Baiyunshan Medicine 白云山医药

The company’s return on total assets was 2.78%, net profit was 1.627 billion, a year-on-year growth rate of 37.47%, revenue in the first quarter was 20.05 billion, a year-on-year increase of 18.02%, non-net profit deducted was 1.592 billion, a year-on-year increase of 33.15%, and the current total market value was 55.8 billion. Dynamic The price-earnings ratio is 8 times.
Analysis: The company is a Chinese medicine company with the most complete varieties in the domestic Chinese medicine industry and the largest number of Chinese time-honored brands and the largest output value.
Site: http://www.byszc.com/

2. Pien Tze Huang 片仔癀药业

The company’s return on total assets was 5.58%, net profit was 565 million, a year-on-year growth rate of 20.48%, revenue in the first quarter was 2.002 billion, a year-on-year increase of 16.76%, and non-net profit was deducted to 559 million, a year-on-year increase of 21.02%. The current total market value is 270.3 billion. Dynamic The price-earnings ratio is 119 times.
Analysis: The leader of traditional Chinese medicine, the “Pienzai” series is everlasting, with an exclusive state-level top-secret formula and strong control over raw materials. The daily chemical business also grew rapidly.
Site: https://www.zzpzh.com/

3. Shanghai Kaibao 上海凯宝药业

The company’s return on total assets was 1.97%, net profit was 57.24 million, a year-on-year growth rate of 8.59%, revenue in the first quarter was 339 million, a year-on-year increase of 15.79%, non-net profit was 56.32 million, a year-on-year increase of 18.14%, and the current total market value was 5.3 billion. Dynamic The price-earnings ratio is 23 times.
Analysis: The company’s leading product, Tanreqing Injection, is an exclusive patented product, a national traditional Chinese medicine protection product, and a national second-class new drug of traditional Chinese medicine.

4. Tongrentang 同仁堂

The company’s return on total assets was 2.14%, net profit was 318.4 million, a year-on-year growth rate of 33.24%, revenue in the first quarter was 3.705 billion, a year-on-year increase of 22.33%, and non-net profit was 316.6 million, a year-on-year increase of 31.68%. The current total market value is 49.8 billion. Dynamic The price-earnings ratio is 39 times.
Analysis: The company is a time-honored enterprise mainly engaged in the production and sales of traditional Chinese patent medicines. It has a wide range of product formulations, including traditional formulations such as pills, powder, pills, and medicinal wine, as well as modern formulations such as tablets, oral liquids, capsules, and granules. .

5. Yunnan Baiyao 云南白药

The company’s return on total assets was 1.4%, net profit was 763.2 million, a year-on-year growth rate of -40.48%, revenue in the first quarter was 10.33 billion, a year-on-year increase of 33.38%, and non-net profit was deducted to 1.365 billion, a year-on-year increase of 29.42%. The current total market value is 138.4 billion, The dynamic price-earnings ratio is 45 times.
Analysis: Based on Yunnan Baiyao, a drug with the highest level of confidentiality in the country, it actively develops the health business.

6. Tai Chi Group 太极集团

The company’s return on total assets was 0.14%, net profit was 24.91 million, a year-on-year growth rate of 180%, revenue in the first quarter was 3.297 billion, a year-on-year increase of 22.91%, non-net profit deducted was 34.79 million, a year-on-year increase of 243%, and the current total market value was 11.9 billion. Dynamic The price-earnings ratio is 119 times.
Analysis: “Taiji” (TAIJI) is the first batch of well-known trademarks in China, and the first OTC brand pharmaceutical company; “Tongjunge” is a century-old brand, and the traditional pill making skills of Tongjunge have entered the national “intangible cultural heritage” protection list .

7. Huangshan Capsule 黄山胶囊

The company’s return on total assets was 1.08%, net profit was 1080 trillion, a year-on-year growth rate of 19.76%, revenue in the first quarter was 104.1 million, a year-on-year increase of 48.14%, and non-net profit was 8.728 million, a year-on-year increase of 16.93%. The current total market value is 2.4 billion, The dynamic price-earnings ratio is 56 times.
Analysis: It has mastered the core technologies such as the preparation and application of advanced enteric coating materials, the production technology of special-type gelatin hollow capsules, and the improvement process of enteric-coated gelatin hollow capsules, and has obtained a number of invention patents and design patents. .

8. Guangyuyuan 广誉远

The company’s return on total assets was 0.13%, net profit was 5.17 million, a year-on-year growth rate of -81.25%, revenue in the first quarter was 190 million, a year-on-year increase of -15.51%, non-net profit deducted was 104.8, a year-on-year increase of -96.3%, and the current total market value was 19.3 billion. , the dynamic price-earnings ratio of 936 times.
Analysis: It has approval numbers for more than 100 traditional Chinese medicines such as Guilingji, Dingkundan, Angong Niuhuang Pill, Niuhuang Qingxin Pill, etc. Among them, Guilingji is the living specimen of the most complete compound refining technology in China so far. Known as the “living fossil of traditional Chinese medicine”, it and Dingkundan are both national secret varieties.

9. Foci Pharmaceuticals 佛慈制药

The company’s return on total assets was 1.05%, net profit was 24.09 million, a year-on-year growth rate of 81.05%, revenue in the first quarter was 177.4 million, a year-on-year increase of 28.61%, and non-net profit was 9.943 million, a year-on-year increase of 6.11%. The current total market value is 4.5 billion. Dynamic The price-earnings ratio is 47 times.
Analysis: The “Buddha” brand was founded in Shanghai in 1929. In the long development of 88 years, it has been widely recognized by the market for its authentic selection of materials, sophisticated craftsmanship and accurate curative effect.

10. Sunflower Pharmaceutical 葵花药业

The company’s return on total assets was 4.75%, net profit was 225.9 million, a year-on-year growth rate of 46.53%, revenue in the first quarter was 1.217 billion, a year-on-year increase of 33.7%, and non-net profit was 215.1 million, a year-on-year increase of 47.32%. The current total market value is 9.4 billion. Dynamic 10 times earnings.
Analysis: The company is a large-scale brand pharmaceutical enterprise group that mainly produces Chinese patent medicines, supplemented by chemical medicines, biopharmaceuticals, and supplementary health care products, and integrates drug research and development, manufacturing and marketing. Efforts will be made to expand core varieties and create golden single product groups.